

PRESS RELEASE

Ad hoc announcement pursuant to article 53 LR

LEPU Medical Technology (Beijing) Announces Results for the First Quarter of 2025

Beijing, China, April 19, 2025- LEPU Medical Technology (Beijing) Co.,Ltd. (the "Company") today announced its performance for the three months ended March 31, 2025:

During the reporting period, the company's operating revenue was RMB 1,736.2313 million, a decrease of RMB 185.7976 million year-on-year, down 9.67%. Revenue entered a stable growth trajectory quarter-on-quarter, increasing by RMB 418.4338 million compared to Q4 2024, up 31.75%.

(1) The medical device segment, the largest contributor to operating revenue, generated RMB 903.7488 million during the reporting period, up 2.05% year-on-year. The cardiovascular intervention business achieved operating revenue of RMB 619.0155 million, a year-on-year increase of 8.49%. Among them, coronary intervention business achieved operating revenue of RMB 446.8958 million, with a year-on-year increase of 2.03%. Structural heart disease business achieved operating revenue of RMB 154.9288 million, with a year-on-year increase of 37.44%. Surgical anesthesia business: The operating income reached RMB 140.1516 million, with a year-on-year increase of 2.53%. In vitro diagnosis business: The operating income reached RMB 88.4425 million, with a year-on-year decrease of 19.87%.

(2) The pharmaceutical segment achieved RMB 594.7917 million, up 111.38% quarter-on-quarter, with retail channel inventory clearance largely completed, the proportion of atorvastatin calcium and clopidogrel bisulfate in the revenue structure has been gradually decreasing. The operating income of active pharmaceutical ingredients reached RMB 83.1147 million, with a quarter-on-quarter increase of 29.35%; The operating income of preparations reached RMB 511.677 million, with a quarter-on-quarter decrease of 135.65%.

(3) The medical services and health management segment generated RMB 237.6908 million during the reporting period.

Due to centralized procurement and policies of "price regulation of four sameness drugs", the gross margin declined by 2.86 percentage points. However, the company's earlier workforce optimization and organizational restructuring began to yield results, reducing both sales and administrative expenses in absolute terms. During the reporting period, the company achieved a net profit of approximately RMB 377.214 million, a year-on-year decrease of 23.45%; achieved a net profit attributable to shareholders of the listed company of RMB 378.5389 million, a year-on-year decrease of 21.44%; and achieved a net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses of RMB 337.3865 million, a year-on-year decrease of 26.08%. During the reporting period, the non-recurring income attributable to shareholders of the listed company was RMB 41.1533 million, compared with a non-recurring income of RMB 25.4373

million in the same period of the previous year, mainly due to the increase in government R&D support received by the company during the reporting period.

Financial Results (unaudited)

| | Current reporting period | Same period of last year | The increase/decrease of the report period from the same period of the previous year (%) |
|---|---------------------------------|--------------------------|--|
| Operating income (RMB) | 1,736,231,253.08 | 1,922,028,839.15 | -9.67% |
| Net profits attributable to shareholders of the listed companies (RMB) | 378,539,846.83 | 481,871,134.58 | -21.44% |
| Net profits attributable to shareholders of the listed company after deducting non-recurring profits and losses (RMB) | 337,386,464.42 | 456,433,815.92 | -26.08% |
| Net cash flow from operating activities (RMB) | 419,022,240.55 | 141,518,257.63 | 196.09% |
| Basic earnings per share (RMB/share) | 0.2053 | 0.2594 | -20.86% |
| Diluted earnings per share (RMB/share) | 0.2053 | 0.2585 | -20.58% |
| Weighted average return on net assets | 2.46% | 2.98% | -0.52% |
| | End of current reporting period | End of the last year | The increase/decrease of the report period from the end of the previous year (%) |
| Total assets (RMB) | 25,233,363,806.46 | 24,573,100,199.19 | 2.69% |
| Owners' equities attributable to shareholders of the Company (RMB) | 15,615,828,015.50 | 15,201,421,378.82 | 2.73% |

Full first quarter report

The full first-quarter results report as of and for the three months ended March 31, 2025 is

available on our website at <https://en.lepumedical.com/investors/>.

Contact information

Ms. Weina Jiang

Phone: +86 010 80120622

E-mail: zqb@lepumedical.com

About LEPU

LEPU Medical Technology(Beijing) Co.,Ltd was the total-solution provider in the PRC across the full life cycle of cardiovascular disease management, with products and services encompassing medical devices, pharmaceuticals, and medical care solutions Company is one of the earliest companies in the PRC to offer coronary interventional products and have consolidated our first-mover advantage through relentless innovation since our inception in 1999. Our key products, namely, coronary drug-eluting stent, coronary bioresorbable scaffold, coronary drug-coated balloon, congenital heart disease occluder and coronary cutting balloon. Our leading R&D expertise and capabilities have enabled us to develop and successfully commercialize a comprehensive portfolio of products. We focus our R&D efforts on unmet clinical needs. We have developed and commercialized the first fully biodegradable occluder in the world and many first Chinese brand products, such as coronary stent, cardiac pacemaker, bioresorbable scaffold and coronary cutting balloon. In addition, we are the first PRC company to apply AI technology to ECG devices. Furthermore, benefiting from our diverse technology platforms, we have developed over 80 product candidates for cardiovascular devices and peripheral artery devices across coronary artery diseases, structural heart diseases, cardiac rhythm management, electrophysiology and other segments.

Disclaimers

This announcement contains forward-looking statements, estimates, opinions and projections with respect to anticipated future performance of the Company ("forward-looking statements"). These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will" or "should" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current views, expectations and assumptions of the management of the Company and involve significant known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Forward-looking statements should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not such results will be achieved. Any forward-looking statements included herein only speak as at the date of this release.